

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/644,052	ATTY. DOCKET NO.: C1037.70048US00	
				FILED DATE: August 19, 2003	CONFIRMATION NO.: 4791	
				APPLICANT: Arthur M. Krieg et al.		
				GROUP ART UNIT: 1645	EXAMINER: Nina Archie	
Sheet	1	of	3			

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,416,203		Letsinger	05-16-1995
		5,696,248		Peyman et al.	12-09-1997
		7,262,286	B2	Kandimalla et al.	08-28-2007
		7,354,711	B2	Macfarlane	04-08-2008
		7,402,572	B2	Krieg et al.	07-22-2008
		7,410,975	B2	Lipford et al.	08-12-2008
		7,488,490	B2	Davis et al.	02-10-2009
		7,517,861	B2	Krieg et al.	04-14-2009
		7,524,828	B2	Krieg et al.	04-28-2009
		7,534,772	B2	Weiner et al.	05-19-2009
		7,566,703	B2	Krieg et al.	07-28-2009
		7,569,553	B2	Kreig	08-04-2009
		7,576,066	B2	Krieg	08-18-2009
		7,585,847	B2	Bratzler et al.	08-18-2009
		2002-0151518	A1	Agrawal et al.	10-17-2002
		2003-0129605	A1	Yu et al.	07-10-2003
		2005-0266015	A1	Clerici et al.	12-01-2005
		2006-0014713	A1	Agrawal et al.	01-19-2006
		2006-0094680	A1	Agrawal et al.	05-04-2006
		2006-0094681	A1	Agrawal et al.	05-04-2006
		2006-0287262	A1	Agrawal et al.	12-21-2006
		2007-0105801	A1	Agrawal et al.	05-10-2007
		2008-0113929	A1	Lipford et al.	05-15-2008
		2008-0152662	A1	Agrawal et al.	06-26-2008
		2008-0226649	A1	Schetter et al.	09-18-2008
		2009-0017021	A1	Davis et al.	01-15-2009
		2009-0060927	A1	Wagner et al.	03-05-2009
		2009-0137519	A1	Krieg et al.	05-28-2009
		2009-0142362	A1	Krieg et al.	06-04-2009
		2009-0155307	A1	Davis et al.	06-18-2009
		2009-0155212	A1	Bratzler et al.	06-18-2009
		2009-0191188	A1	Krieg et al.	07-30-2009
		2009-0202575	A1	Krieg et al.	08-13-2009

	DATE CONSIDERED:
--	------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/644,052	ATTY. DOCKET NO.: C1037.70048US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: August 19, 2003	CONFIRMATION NO.: 4791
			APPLICANT: Arthur M. Krieg et al.	
			GROUP ART UNIT: 1645	EXAMINER: Nina Archie
Sheet	2	of	3	

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
		WO	98/37919	A1	University of Iowa Research Foundation	09-03-1998	
		WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008	
		WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008	
		WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008	
		WO	2008/068638	A2	Coley Pharmaceutical GMBH	06-12-2008	
		WO	2008/139262	A2	Coley Pharmaceutical GMBH	11-20-2008	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998: 525-43.	
		BALLAS et al., Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 1;167(9):4878-86.	
		BHAGAT et al., CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun. 2003 Jan 24;300(4):853-61.	
		FATHI et al., Oligonucleotides with novel, cationic backbone substituents: minoethylphosphonates. Nucleic Acids Res. 1994 Dec 11;22(24):5416-24.	
		HARTMANN et al., Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41.	
		KATAOKA et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. Jpn J Cancer Res. 1992 Mar;83(3):244-7.	
		MARSHALL et al., Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol. 2003 Jun;73(6):781-92.	
		McCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22;19(7-8):950-7.	
		SAMANI et al., Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):129-36.	
		UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel. 2003 Mar;6(2):204-17.	
		VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):165-75.	
		VOLLMER et al., Identification of a new class of CpG oligonucleotides capable of inducing both B cell proliferation and high IFN-alpha secretion from PBMC of HCV chronic carriers. Antiv Ther. 2002;7:L115.	
		VOLLMER et al., Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J Leukoc Biol. 2004 Sep;76(3):585-93. Epub 2004 Jun 24.	

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/644,052	ATTY. DOCKET NO.: C1037.70048US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: August 19, 2003	CONFIRMATION NO.: 4791
				APPLICANT: Arthur M. Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nina Archie
Sheet	3	of	3		

		VOLLMER, CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol. 2006 May-Aug;25(3-4):125-34.	
		VOLLMER, TLR9 in health and disease. Int Rev Immunol. 2006 May-Aug;25(3-4):155-81.	
		WEIGEL et al., CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003 Aug 1;9(8):3105-14.	
		WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7.	
		YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res. 1994 Aug;85(8):775-9.	
		YU et al., 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 2002 Oct 15;30(20):4460-9.	
		YU et al., Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem. 2001 Nov;9(11):2803-8.	
		YU et al., Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun. 2002 Sep 13;297(1):83-90.	

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

	DATE CONSIDERED:
--	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.